AlphAIalphai — Financial news for AI agents
investing.comJUL 284 min read$PMN

ProMIS Neurosciences stock jumps on trial safety data By Investing.com

ProMIS Neurosciences Inc. (NASDAQ:PMN) shares rose about 13% after it reported positive blinded six-month interim safety and biomarker data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s trial. In 136 patients, no ARIA-E was seen; total ARIA was 4.4% and mild. The company expects topline 12-month results in Q1 2027.

Original reporting
investing.com
Published Jul 28, 2026, 11:08 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 28, 2026, 11:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefTechnology
Primary signal
$PMN
Bullish
medium confidence
Mentioned
$PMN
Relevance
8/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$PMNBullishMed
01

Why it matters

The disclosed interim safety profile (no ARIA-E; mild/asymptomatic ARIA-H only; no treatment-related serious adverse events or drug-related discontinuations) directly addresses a key historical constraint for amyloid-directed Alzheimer’s therapies and can sustain investor interest until 12-month topline data.

02

Market read

Traders can treat this as a near-term sentiment catalyst that reduces immediate safety overhang, but efficacy confirmation is still pending.

03

What to watch

ARIA risk can emerge later; the article does not quantify efficacy endpoints, and the biomarker observations are explicitly not a determination of treatment effect.

Relevance 8/10Novelty 7/10Timing: today’s premarket/Tuesday session reaction to interim Phase 1b safety and biomarker data

Background

PMN310 is being tested in PRECISE-AD Phase 1b for Alzheimer’s disease, with a design aimed at binding toxic amyloid-beta oligomers while avoiding plaque to decouple efficacy from ARIA risk.

Company-level read

Ticker impact

$PMNBullishMedium confidence
Context

ProMIS Neurosciences shares jumped 13% after reporting blinded six-month interim safety and biomarker data for PMN310 in PRECISE-AD Phase 1b.

Expected impact

Likely supports continued momentum and reduced downside risk until 12-month topline results in 1Q 2027, though efficacy remains unproven.

Evidence & confidence

The article provides specific interim safety metrics (ARIA-E absent; total ARIA 4.4% mild/asymptomatic; no treatment-related serious AEs or discontinuations) plus blinded biomarker declines, which can drive biotech sentiment even without efficacy determination.

Market effects

Sector

Positive interim safety for an amyloid-oligomer selective approach may improve sentiment toward other Alzheimer’s amyloid-directed programs facing ARIA risk.

Regional

Limited, primarily US small/mid-cap biotech sentiment given the NASDAQ-listed issuer.

Global

Moderate, as Alzheimer’s trial safety signals can influence global biotech risk appetite, but the data are interim and blinded.

Counterpoint

What could challenge this read

Blinded interim biomarker declines are not efficacy, and the trial remains ongoing with topline results still more than a year away.

Key entities

  • company
    ProMIS Neurosciences Inc.

    NASDAQ-listed clinical-stage biopharmaceutical reporting interim blinded safety and biomarker data for PMN310 in PRECISE-AD Phase 1b.

  • drug_candidate
    PMN310

    Selective binder of toxic amyloid-beta oligomers evaluated in Alzheimer’s disease patients.

  • clinical_trial
    PRECISE-AD Phase 1b

    Blinded interim analysis of 136 Alzheimer’s patients with topline 12-month results expected in 1Q 2027.

Read at source← All news

Related articles

JUL 29
$TRIBMed

Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?

Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.

rttnews.com7 min
JUL 28
$PMNMed

Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data

Promis Neurosciences (NASDAQ:PMN) reported interim Phase 1b safety data for PMN310 in Alzheimer’s. As of July 22, there were no ARIA-E cases in the blinded safety population and no treatment-related serious adverse events. Total ARIA was 4.4% (mild, asymptomatic ARIA-H). Biomarkers showed declines in plasma p-tau217 and CSF MTBR-tau243. Dosing runs to Dec 2026; unblinding expected early 2027.

finance.yahoo.com5 min
JUL 28
$PMNMedAI 8/10

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study - ProMI

ProMIS Neurosciences reported a blinded interim safety analysis of PMN310 in an early Alzheimer’s study with 136 patients. It said no ARIA-E cases occurred by the cutoff, total ARIA incidence was 4.4% and limited to mild, asymptomatic ARIA-H. No treatment-related serious adverse events or discontinuations were reported, including in APOE4 carriers. Unblinded 12-month topline results are expected in Q1 2027.

benzinga.com5 min
JUL 28
$PMNMedAI 8/10

Why is ProMIS Neurosciences stock surging today? By Investing.com

ProMIS Neurosciences (PMN) shares rose about 16% pre-open after the company reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310. In 136 patients, there were zero ARIA-E cases, 4.4% total ARIA incidence, and no treatment-related serious adverse events. Chardan started coverage with a Buy and $20 target.

investing.com4 min
JUL 28
$PMNMedAI 8/10

ProMIS Neurosciences Inc.: ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial

ProMIS Neurosciences (Nasdaq: PMN) reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310 in 136 Alzheimer’s patients. As of the cutoff, no ARIA-E occurred and total ARIA was 4.4% (mild, asymptomatic ARIA-H only). Early biomarker shifts in pTau217 and CSF MTBR-tau243 were reported. Unblinded 12-month topline data are expected in Q1 2027.

finanznachrichten.de5 min
JUL 14
$PMNMedAI 8/10

ProMIS Reports First Human PMN310 Target Engagement In Alzheimer's Disease; Stock Up

ProMIS Neurosciences (PMN) reported first human target engagement for its Alzheimer’s candidate PMN310, showing dose-dependent reductions in toxic amyloid-beta oligomers in cerebrospinal fluid at 3 and 29 days after a single dose, with generally good tolerability and a ~27-day half-life. Data were presented at AAIC 2026; PMN310 is in Phase 1b PRECISE-AD, with interim data expected soon.

rttnews.com5 min